Pharmacogenomics

FDA Releases List of Evidence-Based Pharmacogenetic Variants

Pharmacogenetics (PGx) is the study of how an individual’s genetic makeup affects their drug response and metabolism. An understanding of PGx could help clinicians make prescribing decisions and has the potential to be implemented in routine care worldwide. PGx has understandably been gaining traction and support, with pharmacogenomic elements being implemented into many international Genomic studies.

Non-Cancer Drugs Identified to Kill Cancer Cells

Scientists at the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have found that drugs used for inflammation, diabetes, alcoholism, and arthritis also have anti-cancer properties. Published in Nature Cancer, this is the first study to screen an entire collection of mostly non-cancer drugs to see if they can kill cancer cells.

Gene Expression Affected by African Ancestry

A new study by Northwestern Medicine has become the first to compare gene expression levels in African American populations by studying the levels of mRNA expressed in the liver. Previous studies have compared only African and European individuals separately and this study aimed to address the “grey” area of mixed ethnicities.

Cannabis Usage in Fathers Can Cause Inheritable Genetic Changes

Changing Attitudes to Cannabis Cannabis is now legalised for recreational use in 11 US states and attitudes around its risk are changing rapidly. Between 2002 and 2014, the percentage of adults in the US who perceived cannabis use as risky declined from 50% to 33%. However, as cannabis usage becomes more widespread the health risks […]

Maize genome complexity traversed with Oxford Nanopore technology

  Maize is one of the most economically important crops globally and much effort has been spent generating the high quality B73 reference genome. However, the 10 chromosome, 2.3 gigabase (Gb) B73 reference genome was a substantial challenge due to the fact it is comprised of 85% transposable elements, 75% of which are long terminal […]

GSK and 23andMe Agree to $300M Deal

Pharmaceutical giant GlaxoSmithKline has bought a $300 million stake in genetic DTC testing company 23andMe to help further their genetics-based drug discovery.